Skip to content
Venclexta, Venclyxto(venetoclax)
Venclexta, Venclyxto (venetoclax) is a small molecule pharmaceutical. Venetoclax was first approved as Venclexta on 2016-04-11. It is used to treat lymphoid leukemia and myeloid leukemia acute in the USA. It has been approved in Europe to treat b-cell chronic lymphocytic leukemia. The pharmaceutical is active against apoptosis regulator Bcl-2. In addition, it is known to target bcl-2-like protein 1, bcl-2-like protein 2, and induced myeloid leukemia cell differentiation protein Mcl-1.
Download report
Favorite
Case Study: Multiple Myeloma
Top 200 Pharmaceuticals by Retail Sales
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
neoplasmsD009369
hemic and lymphatic diseasesD006425
immune system diseasesD007154
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
Venclexta
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Venetoclax
Tradename
Company
Number
Date
Products
VENCLEXTAAbbVieN-208573 RX2016-04-11
3 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
venclextaNew Drug Application2020-11-23
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
lymphoid leukemia—D007945C91
myeloid leukemia acute—D015470C92.0
Agency Specific
FDA
EMA
Expiration
Code
VENETOCLAX, VENCLEXTA, ABBVIE
2026-05-15ODE-239
2025-11-21ODE-211
2025-06-08ODE-185
2023-10-16M-265
2023-04-11ODE-114
Patent Expiration
Patent
Expires
Flag
FDA Information
Venetoclax, Venclexta, Abbvie
95392512033-09-06U-2538
109939422033-09-06U-3114
111100872033-09-06U-3222, U-3223
114132822033-09-06U-3412
115901282033-09-06U-3548
113695992032-05-23DP
87226572032-01-29DP
107308732031-11-21DP
85463992031-06-27DS, DP
91749822030-05-26U-2323, U-2445, U-2446, U-2537
ATC Codes
L: Antineoplastic and immunomodulating agents
— L01: Antineoplastic agents
— L01X: Other antineoplastic agents in atc
— L01XX: Other antineoplastic agents in atc
— L01XX52: Venetoclax
HCPCS
No data
Clinical
Clinical Trials
456 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Myeloid leukemia acuteD015470C92.093871819166
B-cell chronic lymphocytic leukemiaD015451C91.12552191492
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Myelodysplastic syndromesD009190D4629272——44
Non-hodgkin lymphomaD008228C85.931141—138
Precursor cell lymphoblastic leukemia-lymphomaD054198C91.016141—427
Mantle-cell lymphomaD020522C83.111171——24
Large b-cell lymphoma diffuseD016403C83.319101——23
Multiple myelomaD009101C90.013112—121
NeoplasmsD009369C80943—115
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Myelomonocytic leukemia chronicD015477C93.11313———19
Follicular lymphomaD008224C821310———18
LeukemiaD007938C9528——110
Hematologic neoplasmsD01933765———9
Bcr-abl positive chronic myelogenous leukemiaD015464EFO_000034026———7
LymphomaD008223C85.973———7
Biphenotypic leukemia acuteD015456C95.025———6
Reactive arthritisD016918EFO_0007460M02.326———6
Waldenstrom macroglobulinemiaD008258C88.016———6
Breast neoplasmsD001943EFO_0003869C5042———5
Show 29 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Myeloid leukemiaD007951C922————2
Non-small-cell lung carcinomaD0022892————2
RecurrenceD0120082————2
Pancreatic neoplasmsD010190EFO_0003860C251————1
AnemiaD000740EFO_0004272D64.91————1
Hodgkin diseaseD006689C811————1
SarcomaD0125091————1
ChondrosarcomaD0028131————1
Prolymphocytic leukemiaD0154631————1
Male breast neoplasmsD0185671————1
Show 4 more
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Plasma cell leukemiaD007952C90.1————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameVENETOCLAX
INNvenetoclax
Description
Venetoclax is a member of the class of pyrrolopyridines that is a potent inhibitor of the antiapoptotic protein B-cell lymphoma 2. It is used for treamtment of chronic lymphocytic leukemia with 17p deletion. It has a role as an apoptosis inducer, an antineoplastic agent and a B-cell lymphoma 2 inhibitor. It is a member of oxanes, a N-sulfonylcarboxamide, an aromatic ether, a pyrrolopyridine, a member of monochlorobenzenes, a N-arylpiperazine, a N-alkylpiperazine and a C-nitro compound.
Classification
Small molecule
Drug classbcl-2 (B-cell lymphoma 2) inhibitors
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(Cl)cc2)C1
Identifiers
PDB—
CAS-ID1257044-40-8
RxCUI1747556
ChEMBL IDCHEMBL3137309
ChEBI ID—
PubChem CID49846579
DrugBankDB11581
UNII IDN54AIC43PW (ChemIDplus, GSRS)
Target
Agency Approved
BCL2
BCL2
Organism
Homo sapiens
Gene name
BCL2
Gene synonyms
NCBI Gene ID
596
Protein name
apoptosis regulator Bcl-2
Protein synonyms
B-cell CLL/lymphoma 2, protein phosphatase 1, regulatory subunit 50
Uniprot ID
Q16197
Mouse ortholog
Bcl2 (12043)
apoptosis regulator Bcl-2 (Q4VBF6)
Alternate
BCL2L1
BCL2L1
BCL2L2
BCL2L2
MCL1
MCL1
Organism
Homo sapiens
Gene name
BCL2L1
Gene synonyms
BCL2L, BCLX
NCBI Gene ID
598
Protein name
bcl-2-like protein 1
Protein synonyms
Apoptosis regulator Bcl-X, protein phosphatase 1, regulatory subunit 52
Uniprot ID
Q07817
Mouse ortholog
Bcl2l1 (12048)
bcl-2-like protein 1 (Q64373)
Variants
Clinical Variant
No data
Financial
Venclexta - AbbVie
$
€
£
₣
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 7,905 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
11,525 adverse events reported
View more details